A
ApnimedClinical-stage biotech developing Oxnimbi (AD109), the first investigational oral pill for obstructive sleep apnea.
3 Pulse stories
FT
Flare TherapeuticsFlare Therapeutics is a clinical-stage biotech developing small-molecule drugs that target transcription factors, including a first-in-class ARON-targeting degrader for prostate cancer.
2 Pulse stories
Total Raised
$290M
ApnimedFlare Therapeutics
Last ValuationNot disclosed
Biotech
Sector
Biotech
2017
Founded
2021
Cambridge, Massachusetts
HQ
Cambridge, Massachusetts
Public (APMD)
Status
Private
Apnimed investors
ShionogiColumbia Seligman Technology and Information FundAlpha Wave GlobalMorningside VenturesColumbia ManagementNexPoint Asset ManagementSectoral Asset Management
Flare Therapeutics investors
Third Rock VenturesNextech InvestPfizer VenturesBoxer CapitalGordonMD Global InvestmentsInvusCasdin CapitalEli Lilly and Company
Data from Value Add Pulse coverage and company research — see the full threads for Apnimed and Flare Therapeutics.